2023
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update
Bhatia A, Burtness B. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. Drugs 2023, 83: 217-248. PMID: 36645621, DOI: 10.1007/s40265-023-01835-2.Commentaries, Editorials and LettersConceptsNeck cancerRecurrent/metastatic settingImmune checkpoint inhibitor nivolumabNeck squamous cell carcinomaAge of immunotherapyLate stage HNSCCImmune checkpoint inhibitionPlatinum-containing chemotherapyFirst-line treatmentGrowth factor receptor overexpressionCheckpoint inhibitor nivolumabSquamous cell carcinomaEpidermal growth factor receptor (EGFR) overexpressionPathogenesis of HNSCCTreatment of patientsTreatment of HNSCCManagement of headMonoclonal antibody cetuximabCurative intentPalliative chemotherapyAdvanced diseaseInhibitor nivolumabLocoregional failureMetastatic settingMultimodality therapy
2010
Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy
Bhatia A, Rao A, Ang K, Garden AS, Morrison WH, Rosenthal DI, Evans DB, Clayman G, Sherman SI, Schwartz DL. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head & Neck 2010, 32: 829-836. PMID: 19885924, DOI: 10.1002/hed.21257.Peer-Reviewed Original ResearchConceptsIntensity-modulated radiotherapyAnaplastic thyroid cancerOverall survivalThyroid cancerUse of IMRTEvidence of diseaseMedian radiation doseFull-dose irradiationSuperior survival outcomesKaplan-Meier estimatesCurative intentLocalized diseaseThirteen patientsConsecutive patientsSuch patientsClinical outcomesDistant metastasisSurvival outcomesHealthy patientsConformal radiotherapyPatientsRadiotherapyRadiation doseOutcomesDose irradiation